Log in

Relevant bibliographies by topics / Cancer immunotherapies / Books

Books on the topic 'Cancer immunotherapies'

To see the other types of publications on this topic, follow the link: Cancer immunotherapies.

Author: Grafiati

Published: 10 December 2022

Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 34 books for your research on the topic 'Cancer immunotherapies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Hays, Priya, ed. Cancer Immunotherapies. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-96376-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Ascierto, Paolo A., David F. Stroncek, and Ena Wang, eds. Developments in T Cell Based Cancer Immunotherapies. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-21167-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Martin, Gore, and Riches Pamela, eds. Immunotherapy in cancer. Chichester: Wiley, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

1918-, Yamamura Yūichi, and Azuma Ichiro, eds. Molecular and cellular networks for cancer therapy: From the International Symposium on Molecular and Cellular Networks for Cancer Therapy, May 20, 1988, Osaka, Japan. Amsterdam: Excerpta Medica, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

T, Lotze Michael, Finn Olivera J, and Cetus Corporation, eds. Cellular immunity and the immunotherapy of cancer: Proceedings of a Cetus, Immunex, and Triton Biosciences-UCLA Symposia Colloquium held at Park City, Utah, January 27-February 3, 1990. New York: Wiley-Liss, 1990.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ramakrishnan, S. Cytotoxic conjugates. Austin: R.G. Landes Co., 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

C, Srivastava Suresh, and North Atlantic Treaty Organization. Scientific Affairs Division., eds. Radiolabeled monoclonal antibodies for imaging and therapy. New York: Plenum Press, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Fantini, Massimo, and Roberto Bei, eds. Engineered Targeted Cancer Immunotherapies. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88976-669-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Ascierto, Paolo A., David F. Stroncek, and Ena Wang. Developments in T Cell Based Cancer Immunotherapies. Humana Press, 2015.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Ascierto, Paolo A., David F. Stroncek, and Ena Wang. Developments in T Cell Based Cancer Immunotherapies. Humana, 2015.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

11

Ascierto, Paolo A., David F. Stroncek, and Ena Wang. Developments in T Cell Based Cancer Immunotherapies. Humana, 2019.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

12

Hansen, Morten, Janin Chandra, Fernando Guimaraes, Nicolas Jacquelot, Yoshinobu Koguchi, Nathalie Labarriere, Ilaria Marigo, and Lazar Vujanovic, eds. Cancer Immunotherapies: From Efficacy to Resistance Mechanisms. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88976-441-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Hays, Priya. Cancer Immunotherapies: Solid Tumors and Hematological Malignancies. Springer International Publishing AG, 2022.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

14

Applebaum, Allison J., ed. Cancer Caregivers. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780190868567.001.0001.

Full text

Abstract:

Cancer caregivers are an essential extension of the healthcare team. Rapid advances in cancer care, including new drugs and immunotherapies and more sophisticated diagnostic tools, have improved our ability to extend lives and enhance survival. As patients are living longer and with today’s shorter hospital stays and shift towards increased outpatient care, however, the burden on caregivers and their needs have substantially increased. Cancer Caregivers reveals the depth of complexities of caregiving experiences that the field of Psycho-Oncology has been exploring and the vast expanses we have left to understand. This text describes the characteristics and experiences of cancer caregivers based on their life stage, relationship to the patient, and ethnic group membership, as well as patients’ disease and treatment type. It highlights the significant progress in research focused on the development and dissemination of psychosocial interventions for cancer caregivers, and includes in-depth case studies to illustrate their delivery and application. The text also explores the provision of support to caregivers in the community and the legal and ethical concerns faced by caregivers across the care trajectory. Cancer Caregivers offers both fundamental and practical information and is a resource for all healthcare professionals who work with patients and families facing cancer.

APA, Harvard, Vancouver, ISO, and other styles

15

De, Surya K. Medicines for Cancer: Mechanism of Action and Clinical Pharmacology of Chemo, Hormonal, Targeted, and Immunotherapies. Elsevier, 2023.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

16

De, Surya K. Medicines for Cancer: Mechanism of Action and Clinical Pharmacology of Chemo, Hormonal, Targeted, and Immunotherapies. Elsevier, 2023.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

17

Eisen, Tim. The patient with renal cell cancer. Edited by Giuseppe Remuzzi. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0172.

Full text

Abstract:

Renal cancer is the commonest malignancy of the kidney and worldwide, accounts for between 2% and 3% of the total cancer burden. The mainstay of curative treatment remains surgery. There have been significant advances in surgical technique, the most important ones being nephron-sparing surgery and laparoscopic nephrectomy. The medical treatment of advanced renal cell cancer has only improved markedly in the last decade with the development of antiangiogenic tyrosine-kinase inhibitors, inhibitors of mammalian target of rapamycin, and a diminished role for immunotherapy.Tyrosine-kinase inhibitor therapy results in reduction of tumour volume in around three-quarters of patients and doubles progression-free survival, but treatment is not curative. The management of side effects in patients on maintenance tyrosine-kinase inhibitors has improved in the last 3 years, although still presents difficulties which have to be actively considered.The molecular biology of renal cell carcinoma is better understood than for the majority of solid tumours. The commonest form of renal cancer, clear-cell carcinoma of the kidney, is strongly associated with mutations in the von Hippel–Lindau gene and more recently with chromatin-remodelling genes such as PBRM1. These genetic abnormalities lead to a loss of control of angiogenesis and uncontrolled proliferation of tumour cells. There is a very wide spectrum of tumour behaviour from the extremely indolent to the terribly aggressive. It is not currently known what accounts for this disparity in tumour behaviour.A number of outstanding questions are being addressed in scientific and clinical studies such as a clearer understanding of prognostic and predictive molecular biomarkers, the role of adjuvant therapy, the role of surgery in the presence of metastatic disease, how best to use our existing agents, and investigation of novel targets and therapeutic agents, especially novel immunotherapies.

APA, Harvard, Vancouver, ISO, and other styles

18

Dranoff, Glen, and James Allison. Cancer Immunotherapy. Elsevier Science & Technology Books, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

19

P, Allison James, and Dranoff Glenn, eds. Cancer immunotherapy. Amsterdam: Elsevier Academic Press, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

20

Gore, Martin, and Pamela Riches. Immunotherapy in Cancer. Wiley & Sons, Incorporated, John, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

21

Dranoff, Glen, and James Allison. Cancer Immunotherapy, Volume 90 (Advances in Immunology). Academic Press, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

22

Dranoff, Glen, and James Allison. Cancer Immunotherapy, Volume 90 (Advances in Immunology). Academic Press, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

23

(Editor), Peter L. Stern, Peter C. L. Beverley (Editor), and Miles Carroll (Editor), eds. Cancer Vaccines and Immunotherapy (Cambridge Cancer Series). Cambridge University Press, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

24

G, Crowther D., ed. Interferons: Mechanisms of action and role in cancer therapy. Berlin: Springer-Verlag, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

25

Stern, Peter L., Peter C. L. Beverley, and Miles Carroll. Cancer Vaccines and Immunotherapy. Cambridge University Press, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

26

Stern, Peter L., Peter C. L. Beverley, and Miles Carroll. Cancer Vaccines and Immunotherapy. Cambridge University Press, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

27

Longo, Dan L. Cancer Chemotherapy and Biotherapy: Principles and Practice. Lippincott Williams & Wilkins, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

28

Crowther, D. G. Interferons: Mechanisms of Action and Role in Cancer Therapy (Eso Monographs (European School of Oncology)). Springer, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

29

(Editor), Yuichi Yamamura, and Ichiro Azuma (Editor), eds. Molecular and Cellular Networks for Cancer Therapy (International congress series). Elsevier, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

30

(Editor), K. Kikuchi, B. J. Van Den Eynde (Editor), and N. Sato (Editor), eds. Recent Advances of Human Tumor Immunology and Immunotherapy (Gann Monograph on Cancer Research). Not Avail, 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

31

(Editor), Michael T. Lotze, and Olivera J. Finn (Editor), eds. Cellular Immunity and the Immunotherapy of Cancer (UCLA Symposia on Molecular and Cellular Biology). John Wiley & Sons Inc, 1990.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

32

Debruyne, F. M. J., 1941-, Denis L, Meijden, Ad P. M. van der., European Organization for Research on Treatment of Cancer. Genito-Urinary Tract Cancer Cooperative Group., and International Workshop on BCG in Superficial Bladder Cancer (1st : 1988 : Kerkrade, Netherlands), eds. BCG in superficial bladder cancer: Proceedings of an EORTC Genitourinary Group sponsored meeting held at Erenstein Castle Kerkrade, the Netherlands, on September 7-8, 1988, organized by the Department of Urology, University of Nijmegen, the Netherlands. New York: A.R. Liss, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

33

Between Bench and Bedside: Science, Healing, and Interleukin-2 in a Cancer Ward. Harvard University Press, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

34

1934-, Harris Jules E., Braun Donald P, and Anderson Kenning M, eds. Prostaglandin inhibitors in tumor immunology and immunotherapy. Boca Raton: CRC Press, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!